401 related articles for article (PubMed ID: 26995758)
1. Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery.
Sato Y; Note Y; Maeki M; Kaji N; Baba Y; Tokeshi M; Harashima H
J Control Release; 2016 May; 229():48-57. PubMed ID: 26995758
[TBL] [Abstract][Full Text] [Related]
2. Hydrophobic scaffolds of pH-sensitive cationic lipids contribute to miscibility with phospholipids and improve the efficiency of delivering short interfering RNA by small-sized lipid nanoparticles.
Sato Y; Okabe N; Note Y; Hashiba K; Maeki M; Tokeshi M; Harashima H
Acta Biomater; 2020 Jan; 102():341-350. PubMed ID: 31733331
[TBL] [Abstract][Full Text] [Related]
3. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
Hashiba K; Sato Y; Harashima H
J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA.
Sato Y; Matsui H; Sato R; Harashima H
J Control Release; 2018 Aug; 284():179-187. PubMed ID: 29936118
[TBL] [Abstract][Full Text] [Related]
5. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
[TBL] [Abstract][Full Text] [Related]
6. The development of an in vitro assay to screen lipid based nanoparticles for siRNA delivery.
Zhang Y; Arrington L; Boardman D; Davis J; Xu Y; DiFelice K; Stirdivant S; Wang W; Budzik B; Bawiec J; Deng J; Beutner G; Seifried D; Stanton M; Gindy M; Leone A
J Control Release; 2014 Jan; 174():7-14. PubMed ID: 24240015
[TBL] [Abstract][Full Text] [Related]
7. Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.
Sato Y; Matsui H; Yamamoto N; Sato R; Munakata T; Kohara M; Harashima H
J Control Release; 2017 Nov; 266():216-225. PubMed ID: 28986168
[TBL] [Abstract][Full Text] [Related]
8. Effect of the nanoformulation of siRNA-lipid assemblies on their cellular uptake and immune stimulation.
Kubota K; Onishi K; Sawaki K; Li T; Mitsuoka K; Sato T; Takeoka S
Int J Nanomedicine; 2017; 12():5121-5133. PubMed ID: 28790820
[TBL] [Abstract][Full Text] [Related]
9. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
[TBL] [Abstract][Full Text] [Related]
10. Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.
Suzuki Y; Ishihara H
Int J Pharm; 2016 Aug; 510(1):350-8. PubMed ID: 27374199
[TBL] [Abstract][Full Text] [Related]
11. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
[TBL] [Abstract][Full Text] [Related]
12. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
[TBL] [Abstract][Full Text] [Related]
13. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery.
Alabi CA; Love KT; Sahay G; Yin H; Luly KM; Langer R; Anderson DG
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12881-6. PubMed ID: 23882076
[TBL] [Abstract][Full Text] [Related]
14. Investigating impacts of surface charge on intraocular distribution of intravitreal lipid nanoparticles.
Huang X; Chau Y
Exp Eye Res; 2019 Sep; 186():107711. PubMed ID: 31238078
[TBL] [Abstract][Full Text] [Related]
15. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Delivery of siRNA to Retinal Ganglion Cells by Intravitreal Lipid Nanoparticles of Positive Charge.
Huang X; Chau Y
Mol Pharm; 2021 Jan; 18(1):377-385. PubMed ID: 33295773
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
[TBL] [Abstract][Full Text] [Related]
18. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
Basha G; Novobrantseva TI; Rosin N; Tam YY; Hafez IM; Wong MK; Sugo T; Ruda VM; Qin J; Klebanov B; Ciufolini M; Akinc A; Tam YK; Hope MJ; Cullis PR
Mol Ther; 2011 Dec; 19(12):2186-200. PubMed ID: 21971424
[TBL] [Abstract][Full Text] [Related]
19. Development of an Alcohol Dilution-Lyophilization Method for Preparing Lipid Nanoparticles Containing Encapsulated siRNA.
Shirane D; Tanaka H; Nakai Y; Yoshioka H; Akita H
Biol Pharm Bull; 2018; 41(8):1291-1294. PubMed ID: 30068880
[TBL] [Abstract][Full Text] [Related]
20. Single-step microfluidic synthesis of transferrin-conjugated lipid nanoparticles for siRNA delivery.
Li Y; Lee RJ; Huang X; Li Y; Lv B; Wang T; Qi Y; Hao F; Lu J; Meng Q; Teng L; Zhou Y; Xie J; Teng L
Nanomedicine; 2017 Feb; 13(2):371-381. PubMed ID: 27720989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]